Navigation Links
Pharmasset Reports Fiscal Second Quarter 2009 Financial Results
Date:5/11/2009

RM-1 trial as an oral late breaker at the European Association for the Study of the Liver (EASL) in Copenhagen, Denmark. This is the first study to investigate the activity of a combination of two oral antiviral molecules to treat HCV in the absence of interferon. The study is investigating the combination of Pharmasset's R7128, a nucleoside inhibitor, with InterMune's R7227, a protease inhibitor;
  • On April 24, 2009, Pharmasset announced that its development partner, Roche, had initiated dosing of patients in the phase 2b trial of R7128 in combination with the standard of care in genotype 1 and 4 HCV infected patients. The start of the trial triggered a $10.0 million milestone payment to Pharmasset that is expected to be received in the quarter ending June 30, 2009;
  • On April 20, 2009, Pharmasset announced that it had voluntarily halted its phase 3 registration studies of clevudine for the treatment of chronic hepatitis B infection;
  • On March 31, 2009, Pharmasset announced the dosing of the first healthy volunteer in the phase 1 trial with PSI-7851, a second generation nucleotide inhibitor of HCV.

  • "Our HCV pipeline continues to make solid progress," stated Schaefer Price, President and Chief Executive Officer. "In April, we announced exciting data from the INFORM-1 trial at EASL and the initiation of the phase 2b trial with R7128. We are now able to increase our focus on further strengthening our portfolio of HCV nucleos(t)ides with the decision to halt registration studies with clevudine. We look forward to providing the first antiviral data on PSI-7851 in the second half of 2009."

    Calendar Year 2009 Anticipated Milestones:

    • Announce selection of candidate(s) from our purine series of nucleos(t)ide analog for HCV in second half of 2009;
    • Provide update on safety from first 100 patients in t
      '/>"/>

    SOURCE Pharmasset, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
    2. Pharmasset to Present at the UBS Global Life Sciences Conference on Monday, September 24th
    3. Pharmasset Accesses up to $30 Million of Working Capital
    4. Pharmasset to Present at Three Investor Conferences in November 2007
    5. Pharmasset Appoints Michael Rogers as Chief Development Officer
    6. Pharmasset Reports Fiscal Year End 2007 Financial Results
    7. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
    8. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
    9. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
    10. Pharmasset Appoints Herbert J. Conrad as a Director
    11. Pharmasset Receives $10 Million of Working Capital
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... Pipette.com announces their Holiday in ... submit their #HolidayInTheLab pictures for a chance to win ... For those struggling to think of a holiday gift ... the Lab Contest provides the ideal holiday presents. The ... send pictures of their chemistree, holiday sweaters, as well ...
    (Date:12/24/2014)... -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI ) ... Application (CTA) with the United Kingdom,s ... approval to initiate clinical trials for the continued development ... on the Company receiving CTA regulatory approval, the Company ... the safety, tolerability and dose escalation of Anatabine Citrate ...
    (Date:12/22/2014)... CHAPEL HILL, N.C. , Dec. 22, 2014 ... ALNE) today announced that it has signed a ... biotechnology company that has developed and patented a ... and medical diagnostics products that enable rapid on-site ... and alcohol use/abuse and health issues in an ...
    (Date:12/22/2014)... Fertility Associates of Memphis has announced ... , a network of more than 20 contributing ... have fast access to a national pool of frozen ... Fertility Associates of Memphis is the only fertility clinic ... , Dr. William Kutteh , director of Fertility ...
    Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3ALNE Announces Intention To Acquire BioTechPharma 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3
    ... , , , BEIJING , Feb. 8 ... in-vitro,diagnostic ("IVD") company, today announced that it will participate at the,following investor conferences in March 2010 : ... Location, ... Hotel, China Investment ...
    ... , NEW YORK , Feb. 8 ... relations and corporate communications for domestic and international clients, announced ... have joined as Managing Directors. , “Lisa and ... serve our clients well,” said Lynn Morgen , co-founder ...
    ... , , , , ... 3SBio Inc. (Nasdaq:, SSRX ) ("3SBio" or "the Company"), ... developing, manufacturing and marketing,biopharmaceutical products, today announced a collaboration ... commercialize its,Nephoxil(R) pharmaceutical product for the treatment of hyperphosphatemia ...
    Cached Biology Technology:China Medical Technologies to Participate Investor Conferences in March 2010 2MBS Value Partners Hires Two New Senior Staff Members 23SBio and Panacor Bioscience Enter Collaboration and License Agreement to Develop and Commercialize Nephoxil(R) for Hyperphosphatemia 23SBio and Panacor Bioscience Enter Collaboration and License Agreement to Develop and Commercialize Nephoxil(R) for Hyperphosphatemia 33SBio and Panacor Bioscience Enter Collaboration and License Agreement to Develop and Commercialize Nephoxil(R) for Hyperphosphatemia 4
    (Date:12/19/2014)... Dec. 18, 2014 Research and Markets ... "Micro Market Monitor: North America Perimeter Security Systems ... http://photos.prnewswire.com/prnh/20130307/600769 The North American ... CAGR of 3.6% from 2014 to 2019. Although the ... Canada is expected to grow ...
    (Date:12/17/2014)... 15, 2014  HITLAB SM announced today ... audit to confirm its adherence to current U.S. ... enables HITLAB to conduct regulated smart device and ... for patient safety and research quality. ... quality, and delivery with innovative technology," said ...
    (Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) ... Market in the APAC Region 2015-2019"  report to ... emerging in this market is advances in technology. ... to upgrade biometric solutions to the latest standard ...
    Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
    ... infected with human immunodeficiency virus (HIV), highly active ... of Kaposi sarcoma and non-Hodgkin lymphoma, according to ... of the Journal of the National Cancer Institute. ... (AIDS) have reported increased risks of several cancers, ...
    ... short pulses is a promising, non-invasive procedure for ... healthy tissue, according to a study in the ... focused ultrasound (HIFU) is more powerful than standard ... continuous exposures that raise the temperature inside cancerous ...
    ... the NIH new policy from yesterday : ... rule on Enhanced Public Access to NIH Research Information ... opportunity to take advantage of available technology and existing ... not-for-profit medical and scientific publishers. The final rule ignores ...
    Cached Biology News:Antiretroviral therapy may prevent excess risk of some cancers in people with HIV 2Pulsating ultrasound enhances gene therapy for tumors 2Not-for-profit publishers call NIH public access rule a missed opportunity 2Not-for-profit publishers call NIH public access rule a missed opportunity 3
    Request Info...
    ... The Zero Blunt ... for Sequencing is designed ... sequencing of blunt-end PCR ... provides 5-minute TOPO Cloning ...
    ... 1 kit. Convenient way to ... Conjugations are carried out under mild conditions ... Dyes are packaged in premeasured amounts and ... Category: Blotting & Labeling & Detection, Protein ...
    ...
    Biology Products: